Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs

Atherosclerosis

Volumn 146, Issue 2, 1999, Pages 259-270

  Suzuki, Hideo ^a   Aoki, Taro ^a   Tamaki, Taro ^a   Sato, Fumiyasu ^a   Kitahara, Masaki ^b   Saito, Yasushi ^c  

^a KOWA COMPANY LTD   (Japan)

^b NISSAN CHEMICAL INDUSTRIES LTD   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Fractional catabolic rate; Guinea pig; HMG CoA reductase inhibitor; Liver perfusion; Low density lipoprotein receptor; NK 104; Very low density lipoprotein secretion

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PITAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GUINEA PIG; HYPERCHOLESTEROLEMIA; LIVER PERFUSION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEROL SYNTHESIS;

ANIMALS; ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; CHOLESTEROL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GUINEA PIGS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPOPROTEINS, VLDL; LIVER; MALE; QUINOLINES; RECEPTORS, LDL; SIMVASTATIN; STEROLS; TRIGLYCERIDES;

EID: 0032822196     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00146-X     Document Type: Article

References (64)

1. Gotto A.M. Jr. Cholesterol management in theory and practice. Circulation. 96:1997;4424-4430.
2. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlene P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med. 333:1995;1301-1307.
3. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
4. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypath grafts. New Engl J Med. 336:1997;153-162.
5. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., Zhao X.Q., Bisson B.D., Fitzpatrick V.F., Dodge H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New Engl J Med. 323:1990;1289-1298.
6. Kroon A.A., Aengevaeren W.R., van der Werf T., Uijen G.J., Reiber J.H., Bruschke A.V., Stalenhoef A.F. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 93:1996;1826-1835.
7. Fager G., Wiklund O. Cholesterol reduction and clinical benefit. Are there limits to our expectations? Arterioscler Thromb Vasc Biol. 17:1997;3527-3533.
8. Packard C.J., Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 17:1997;3542-3556.
9. Weintraub M.S., Grosskopf I., Rassin T., Miller H., Charach G., Rotmensch H.H., Liron M., Rubinstein A., Iaina A. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. Br Med J. 312:1996;935-939.
10. Superko H.R. Beyond LDL cholesterol reduction. Circulation. 94:1996;2351-2354.
11. Kesäniemi Y.A. Relevance of the reduction of triglycerides in the prevention of coronary heart disease. Curr Opin Lipidol. 9:1998;571-574.
12. Sattar N., Packard C.J., Petrie J.R. The end of triglycerides in cardiovascular risk assessment? Rumours of death are greatly exaggerated. Br Med J. 317:1998;553-554.
13. Anber V., Millar J.S., McConnell M., Shepherd J., Packard C.J. Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler Thromb Vasc Biol. 17:1997;2507-2514.
14. Murakami T., Michelagnoli S., Longhi R., Gianfranceschi G., Pazzucconi F., Calabresi L., Sirtori C.R., Franceschini G. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol. 15:1995;1819-1828.
15. Brinton E.A., Eisenberg S., Breslow J.L. Human HDL cholesterol levels are determined by apo A-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb. 14:1994;707-720.
16. Horowitz B.S., Goldberg I.J., Merab J., Vanni T.M., Ramakrishnan R., Ginsberg H.N. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest. 91:1993;1743-1752.
17. Millar J.S., Packard C.J. Heterogeneity of apolipoprotein B-100-containing lipoproteins: what we have learnt from kinetic studies. Curr Opin Lipidol. 9:1998;197-202.
18. Ooi T.C., Heinonen T., Alaupovic P., Davignon J., Leiter L., Lupien P.J., Sniderman A.D., Tan M.H., Tremblay G., Sorisky A., Shurzinske L., Black D.M. Efficacy and safety of a new hydroxymethyl glutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. Arterioscler Thromb Vasc Biol. 17:1997;1793-1799.
19. Farnier M. Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. The Cerivastatin Study Group: Cerivastatin Gemfibrozil Hyperlipidemia Treatment. Am J Cardiol. 82:1998;47J-51.
20. Aoki T., Nishimura H., Nakagawa S., Kojima J., Suzuki H., Tamaki T., Wada Y., Yokoo N., Sato F., Kimata H., Kitahara M., Toyoda K., Sakashita M., Saito Y. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneim-Forsh/Drug Res. 47:1997;904-909.
21. Yamada Y, Goto Y, Saito Y, NK-104 Clinical Evaluation Committee. Clinical effect of NK-104 (Nisvastatin) on hyperlipidemia - double-blind comparative dose-finding study in three parallel groups. Proceedings of the XIII International Symposium on Drugs Affecting Lipid Metabolism 1998:129 (Abstract).
22. Davidson M.H., Stein E.A., Dujovne C.A., Hunninghake D.B., Weiss S.R., Knopp R.H., Illingworth D.R., Mitchel Y.B., Melino M.R., Zupkis R.V., Dobrinska M.R., Amin R.D., Tobert J.A. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol. 79:1997;38-42.
23. Bruckert E., De Gennes J.L., Malbecq W., Baigts F. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. Clin Cardiol. 18:1995;621-629.
24. Havel R.J., Eder H.A., Bradgon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 34:1955;1345-1353.
25. Bilheimer D.W., Goldstein J.L., Grundy S.M., Brown M.S. Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia. J Clin Invest. 56:1975;1420-1430.
26. Kovanen P.T., Brown M.S., Basu S.K., Bilheimer D.W., Goldstein J.L. Saturation and suppression of hepatic lipoprotein receptor: a mechanism for the hypercholesterolemia of cholesterol-fed rabbits. Proc Natl Acad Sci USA. 78:1981;1396-1400.
27. Thomas L.I., Robert E.P., Robert W.M. Lipoprotein-receptor interactions. Albers J.J., Segrest J.P. Methods in enzymology. Plasma lipoproteins part B. Characterization, cell biology, and metabolism. 129:1986;542-565 Academic Press, London.
28. Gaw A., Packard C.J., Shepherd J. Lipoprotein turnover and metabolism. Converse C.A., Skinner E.R. Lipoprotein analysis. A practical approach. 1992;119-144 Oxford University Press, New York.
29. Teramoto T., Watanabe T., Matsushima T., Horie Y., Oka H. Characterization of nascent lipoproteins produced by perfused rat liver: evidence of hepatic secretion and post-secretory modification of nascent lipoproteins. J Biochem. 107:1990;519-525.
30. Hamilton R.L., Berry M.N., Williams M.C., Severinghaus E.M. A simple and inexpensive membrane 'lung' for small organ perfusion. J Lipid Res. 15:1974;182-186.
31. Berglund L., Shakey M.F., Elam R.L., Witztum J.L. Effects of lovastatin therapy on guinea pig low density lipoprotein composition and metabolism. J Lipid Res. 30:1989;1591-1600.
32. Berglund L.F., Beltz W.F., Elam R.L., Witztum J.L. Altered apolipoprotein B metabolism in very low density lipoprotein from lovastatin-treated guinea pigs. J Lipid Res. 35:1994;956-965.
33. Pease R.J., Leiper J.M. Regulation of hepatic apolipoprotein-B-containing lipoprotein secretion. Curr Opin Lipidol. 7:1996;132-138.
34. Zhou M., Fisher E.A., Ginsberg H.N. Regulated Co-translational ubiquitination of apolipoprotein B100. A new paradigm for proteasomal degradation of a secretory protein. J Biol Chem. 273:1998;24649-24653.
35. Fielding C.J., Fielding P.E. Intracellular cholesterol transport. J Lipid Res. 38:1997;1503-1521.
36. Huff M.W., Burnett J.R. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Curr Opin Lipidol. 8:1997;138-145.
37. Nohturfft A., Brown M.S., Goldstein J.L. Topology of SREBP cleavage-activating protein, a polytopic membrane protein with a sterol-sensing domain. J Biol Chem. 273:1998;17243-17250.
38. Sakai J., Nohturfft A., Goldstein J.L., Brown M.S. Cleavage of sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction with SREBP cleavage-activating protein. Evidence from in vivo competition studies. J Biol Chem. 273:1998;5785-5793.
39. Stein E.A., Lane M., Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 81:1998;66B-69.
40. Williams K.J., Petrie K.A., Brocia R.W., Swenson T.L. Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro. A possible pathophysiologic explanation for familial combined hyperlipidemia. J Clin Invest. 88:1991;1300-1306.
41. Conde K., Vergara-Jimenez M., Krause B.R., Newton R.S., Fernandez M.L. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J Lipid Res. 37:1996;2372-2382.
42. Blum C.B. Dynamics of apolipoprotein E metabolism in humans. J Lipid Res. 23:1982;1308-1316.
43. Morton R.E., Greene D.J. Suppression of lipid transfer inhibitor protein activity by oleate. A novel mechanism of cholesteryl ester transfer protein regulation by plasma free fatty acids. Arterioscler Thromb Vasc Biol. 17:1997;3041-3048.
44. Huff M.W., Telford D.E. Regulation of low density lipoprotein apoprotein B metabolism by lovastatin and cholestyramine in miniature pigs: effects on LDL composition and synthesis of LDL subfractions. Metabolism. 38:1989;256-264.
45. Burnett J.R., Wilcox L.J., Telford D.E., Kleinstiver S.J., Barrett P.H., Newton R.S., Huff M.W. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Arterioscler Thromb Vasc Biol. 17:1997;2589-2600.
46. Krause B.R., Newton R.S. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis. 117:1995;237-244.
47. Yamamoto K, Todaka N, Goto H, Jayasooriya AP, Sakono M, Ogawa Y, Fukuda N. Effect of NK-104, a new synthetic HMG-CoA reductase inhibitor, on triglyceride secretion and fatty acid oxidation in rat liver. Life Sciences (submitted).
48. Kimata H, Kojima J, Fujino H, Koide T, Yamada Y, Yoshimura M, Nakabeppu H, Nakaya N, Saito Y. Pharmakokinetics of NK-104 (Nisvastatin) in animals and human. Proceedings of the XIII International Symposium on Drugs Affecting Lipid Metabolism 1998;63 (abstract).
49. Cilla D.D. Jr., Whitfield L.R., Gibson D.M., Sedman A.J., Posvar E.L. Multiple-dose pharmacokinetics, pharmacodynamics and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther. 60:1996;687-695.
50. Williams K.J., Brocia R.W., Fisher E.A. The unstirred water layer as a site of control of apolipoprotein B secretion. J Biol Chem. 265:1990;16741-16744.
51. Berglund L., Witztum J.L., Galeano N.F., Khouw A.S., Ginsberg H.N., Ramakrishnan R. Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach. J Lipid Res. 39:1998;913-924.
52. Ness G.C., Zhao Z., Lopez D. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch Biochem Biophys. 325:1996;242-248.
53. Lopez D., Ness G.C. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase unmask transcriptional regulation of hepatic low-density lipoprotein receptor gene expression by dietary cholesterol. Arch Biochem Biophys. 344:1997;215-219.
54. Auerbach B.J., Krause B.R., Bisgaier C.L., Newton R.S. Comparative effects of HMG-CoA reductase inhibitors on apoB production in the casein-fed rabbit: atorvastatin versus lovastatin. Atherosclerosis. 115:1995;173-180.
55. Matsunaga A., Sasaki J., Takada Y., Hidaka K., Arakawa K. Effect of simvastatin on receptor mediated metabolism of low density lipoprotein in guinea pigs. Atherosclerosis. 90:1991;31-37.
56. Matsunaga A., Sasaki J., Hidaka K., Takada Y., Araki K., Moriyama K., Arakawa K. Pravastatin-induced changes in receptor-mediated metabolism of low density lipoprotein in guinea pigs. Artery. 21:1994;94-113.
57. Morikawa S, Umetani M, Nakagawa S, Yamazaki H, Suganami H, Inoue K, Kitahara M, Hamakubo T, Kodama T, Saito Y. The relative induction of messenger RNA for 3-hydroxy-3-methylglutaryl coenzyme A reductase and low density lipoprotein receptor by five different HMG-CoA reductase inhibitors in cultured human cells. Atherosclerosis (submitted).
58. Aguilar-Salinas C.A., Barrett H., Schonfeld G. Metabiolic modes of action of the statins in the hyperlipoproteinemias. Atherosclerosis. 141:1998;203-207.
59. Ginsberg H.N. Effects of statins on triglyceride metabolism. Am J Cardiol. 81:1998;32B-35.
60. Hagan D.L., Kienzle B., Jamil H., Hariharan N. Transcriptional regulation of human and hamster microsomal triglyceride transfer protein genes. Cell type-specific expression and response to metabolic regulators. J Biol Chem. 269:1994;28737-28744.
61. Hara E, Yotsumoto H, Yamamoto K, Yanagita T. A potent new HMG-CoA reductase inhibitor, NK-104, enhances posttranslational catabolism of apoB and inhibits the secretion of triacylglycerols in HepG2 cells. Curr Ther Res (submitted).
62. Bischoff H., Angerbauer R., Bender J., Bischoff E., Faggiotto A., Petzinna D., Pfitzner J., Porter M.C., Schmidt D., Thomas G. Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis. 135:1997;119-130.
63. Steinke W., Yamashita S., Tabei M., Ahr H.J., Beckermann B., Domdey-Bette A., Göller G., Schwarz T., Siefert H.M. Cerivastatin, a new inhibitor of HMG-CoA reductase - Pharmacokinetics in rats and dogs. Jpn Pharmacol Ther. 24:1996;S1217-S1237.
64. McClelland G.A., Stubbs R.J., Fix J.A., Pogany S.A., Zentner G.M. Enhancement of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor efficacy through administration of a controlled-porosity osmotic pump dosage form. Pharm Res. 8:1991;873-876.